CYP17A1 and ovarian cancer: This can be blocked by ER antagonists (e.g. fulvestrant).29 The combination of CYP17 inhibition (abiraterone) with drugs such as enzalutamide as an AR antagonist or fulvestrant (ER antagonist) may be worth investigating in ovarian cancer.